Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(7)
MIXED(4)
Laboratory Biomarker Analysis
2 trials
early_phase_1phase_1
md-anderson-cancer-center
BMN 673
1 trial
early_phase_1
md-anderson-cancer-center
Ceralasertib
1 trial
phase_2
md-anderson-cancer-center
Biospecimen Collection
1 trial
md-anderson-cancer-center
Adavosertib
1 trial
phase_2
md-anderson-cancer-center
Paclitaxel/Bev + ZA (experimental)
1 trial
early_phase_1
md-anderson-cancer-center
EphA2-targeting DOPC-encapsulated siRNA
1 trial
phase_1
md-anderson-cancer-center
Olaparib
1 trial
phase_2
md-anderson-cancer-center

+2 more interventions

10 unique interventions2 categories

Analytics

Trial Phases

Phase 11
Phase 21

Trial Status

Completed2
Other3

Role Distribution

Principal Investigator5
PI Rate100%

Activity Timeline

Clinical Trials (5)

NCT05053750Early Phase 1Active Not Recruiting
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epithelial OvarianFallopian TubePrimary Peritoneal Cancer
PrincipalinvestigatorStart date: 2021-12-14
NCT03579316Phase 2Active Not Recruiting
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
PrincipalinvestigatorStart date: 2018-12-07
NCT01591356Phase 1Active Not Recruiting
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
Advanced Malignant Solid Neoplasm
PrincipalinvestigatorStart date: 2015-07-01
NCT02316834Early Phase 1Completed
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaOvarian Mass+16 more
PrincipalinvestigatorStart date: 2015-06-02
NCT02093546Completed
Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290
Recurrent Endometrial Carcinoma
PrincipalinvestigatorStart date: 2004-08-13

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Shannon N Westin

M.D. Anderson Cancer Center

Related
7 trials

Shared therapeutic areas:

High Grade Ovarian Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+17 more

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)
Similarity Score22%

Emese Zsiros

Roswell Park Cancer Institute

Related
6 trials

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Amir A Jazaeri

M.D. Anderson Cancer Center

Related
7 trials

Shared therapeutic areas:

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+2 more

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)
Similarity Score6%

Lilie L Lin

M.D. Anderson Cancer Center

Related
5 trials

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+1 more

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)
Similarity Score4%

Carol Aghajanian, MD

Memorial Sloan Kettering Cancer Center

Related
5 trials

Shared therapeutic areas:

Fallopian TubesPrimary Peritoneal Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Paul Sabbatini, MD

Memorial Sloan Kettering Cancer Center

Related
14 trials

Shared therapeutic areas:

Fallopian TubesPrimary Peritoneal Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

A P Chen

National Cancer Institute LAO

Related
8 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmRecurrent Ovarian Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Stephanie Lheureux, M.D.

Princess Margaret Cancer Centre

Related
5 trials

Shared therapeutic areas:

Primary Peritoneal Cancer
Similarity Score1%

David Hui, MD

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Advanced Malignant Solid Neoplasm

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)
Similarity Score1%

Anthony El-Khoueiry, MD

University of Southern California

Related
6 trials

Shared therapeutic areas:

Advanced Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT05053750Early Phase 1PrincipalInvestigator

TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Epithelial OvarianFallopian TubePrimary Peritoneal Cancer
Active Not Recruiting
NCT03579316Phase 2PrincipalInvestigator

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Active Not Recruiting
NCT01591356Phase 1PrincipalInvestigator

EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors

Advanced Malignant Solid Neoplasm
Active Not Recruiting
NCT02316834Early Phase 1PrincipalInvestigator

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaOvarian Mass+16 more
Completed
NCT02093546PrincipalInvestigator

Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290

Recurrent Endometrial Carcinoma
Completed

All 5 trials loaded